biotech / news / / The Manila Times
Revolution Medicines, Inc. is a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers.
Daraxonrasib showed unprecedented overall survival benefit in Phase 3 RASolute 302 trial for metastatic PDAC.
KEY POINTS
- Daraxonrasib met all primary and key secondary endpoints versus standard chemotherapy in treated metastatic PDAC.
- RASolute 302 trial included patients with diverse RAS variants, including those without identified RAS mutations.
- Daraxonrasib received FDA Breakthrough Therapy and Orphan Drug Designations for metastatic PDAC with G12 mutations.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →